Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Blood

Volumn 109, Issue 1, 2007, Pages 58-60

  Rousselot, Philippe ^a,b   Huguet, Francoise ^c   Rea, Delphine ^a   Legros, Laurence ^d   Cayuela, Jean Michel ^e   Maarek, Odile ^e   Blanchet, Odile ^f   Marit, Gerald ^g   Gluckman, Eliane ^a   Reiffers, Josy ^h   Gardembas, Martine ^f   Mahon, François Xavier ⁱ  

^a SAINT LOUIS HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c CHU PURPAN   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e Laboratoire Central d'Hematologie   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h INSTITUT BERGONIÉ   (France)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IMATINIB; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33846023983     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-011239     Document Type: Article

References (10)

1. Kim Y-J, Kim D-W, Lee S, et al. Monitoring of BCR-ABL transcript levels after discontinuation of imatinib therapy in chronic myelogenous leukemia patients achieving complete cytogenetic response [abstract]. Blood. 2004;104:255b. Abstract 4684.
2. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
3. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214-220.
4. Hughes TP, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase
5. domain mutations and for expressing results. Blood. 2006;108:28-37.
6. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104:2204-2205.
7. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28(suppl 1):S71-S73.
8. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:979-981.
9. Goldman JM, Hughes T, Radich J, et al. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS study [abstract]. Blood. 2005;106:51a. Abstract 163.
10. Michor F, Hughes T, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435:1267-1270.